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Abstract
Background: The management of diabetic patients with refractory macular oedema or patients
with no adequate pre-operative view to administer laser treatment provide a challenge to the
ophthalmologist. We wished to assess the use, safety and effect of intravitreal triamcinolone
injection at the time of cataract surgery in patients with diabetic foveal oedema and sight limiting
lens opacities.
Method: This was a longitudinal non-randomised prospective pilot study in 18 eyes (12 patients).
All patients had visually significant lens opacities and either persistent diabetic foveal oedema
unresponsive to laser treatment-group A, or foveal oedema with no adequate pre-operative view
for laser treatment- group B. The cataract surgery was carried out under full aseptic technique
using a self-sealing temporal incision and a foldable acrylic lens. Intravitreal triamcinolone was given
infratemporally pars plana at the completion of the cataract surgery. The patients were reviewed
at day 5, 2 weeks, 2 months and then every 3 months as required. The Wilcoxin matched-pairs test
was used to assess the significance of the improvement in visual acuity at 2 months.
Results: Twelve patients with a total of 18 eyes were included in the study. There were 10 patients
(15 eyes) in group A and 3 patients (3 eyes) in group B. Preoperatively 16 of the 18 eyes had a visual
acuity of 6/24 or worse. Postoperatively 83% of patients had completely dry foveae at 2 weeks.
Best-corrected visual acuities at two months review ranged from 6/6 to CF with 9 eyes (50%)
achieving 6/12 or better (7 eyes (47%) in group A and 2 eyes (67%) in group B). Three eyes had no
recorded improvement in visual acuity, but no eyes had deterioration in acuity. The improvement
in visual acuity was significant at p = 0.001. There were no significant sight threatening
complications.
Conclusion: Intravitreal triamcinolone has been shown to lead to an improvement in macular
oedema and visual improvement in diabetic patients not undergoing cataract surgery but has not,
to our knowledge, been previously used in a study like this one.
We suggest that intravitreal injection at the time of cataract surgery could be carried out safely 
with encouraging visual outcomes in patients with diabetic foveal oedema and cataract.
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Background
Diabetes mellitus is the most common predisposing risk
factor for cataracts in the developed world with a three to
four fold increased prevalence in people under 65 [1]. It is
an important cause of reduced vision [2] and it has been
estimated that up to 20% of all cataract surgery is per-
formed on diabetic patients [3].
Cataract surgery in patients with diabetic retinopathy is
associated with an increased risk of a number of problems
including uveitis [4], posterior capsule opacity [5], and
anterior capsule phimosis [6]. Some studies have found
an increased risk of retinopathy progression and in partic-
ular macular oedema exacerbation with cataract surgery
[7-12]. Cataracts can also impair the recognition of sight
threatening retinopathy and obstruct treatment of
maculopathy.
It is thought that the incidence of these complications and
the visual outcome is related to the severity of the retinop-
athy and its activity at the time of surgery as well as glycae-
mic control [12,13]. Patients with no retinopathy have an
excellent prognosis [14,15]. However, patients with mac-
ular oedema have a poor visual prognosis [14-21]. Macu-
lar oedema presenting de novo immediately following
cataract surgery can spontaneously resolve with a good
result, and patients with previously successfully treated
macular oedema do well with cataract surgery [22]. How-
ever persistent macular oedema despite laser or macular
oedema either undetected or untreatable prior to surgery
does not resolve spontaneously. These patients have a
substantially impaired prognosis [14-21].
Although laser photocoagulation can be applied post-
operatively it can be difficult to perform immediately fol-
lowing surgery, because of problems such as photopho-
bia, contact lens intolerance, poor mydriasis, intraocular
lens deposits and edge effects, posterior capsule opacity or
vitreous haemorrhage. Intra-operative pan retinal photo-
coagulation (PRP) can be applied with an indirect oph-
thalmoscope, however intra-operative focal laser applied
in this way is imprecise. It is recognised that the increased
blood ocular barrier breakdown associated with pan reti-
nal photocoagulation can potentially exacerbate macular
oedema [23].
Intravitreal triamcinolone has been successfully used to
treat patients with refractory diffuse diabetic macular
oedema [24-26] and patients with refractory pseudopha-
kic macular oedema [27,28]. It has also been shown to
reduce blood ocular barrier break down following PRP
[29].
We designed an initial pilot study to assess the ease of use,
safety and effect of intravitreal triamcinolone injection at
the time of cataract surgery in patients with sight limiting
cataract and diabetic foveal macular oedema.
Methods
We carried out a longitudinal pilot study of 12 patients
(18 eyes) undergoing phacoemulsification cataract sur-
gery. Inclusion criteria was visually significant cataract
with either:
a) Pre-existing and persistent diabetic foveal oedema
unresponsive to laser treatment as per ETDRS recommen-
dations [30] – Group A.
b) Foveal oedema with no adequate view to perform pre-
operative laser – Group B.
Exclusion criteria included a known increased intraocular
pressure response to steroids and glaucoma. Fully
informed consent was taken. Patients were examined
immediately prior to surgery by recording the best-cor-
rected visual acuity, intraocular pressure and slit lamp
biomicroscopy using a 66 dioptre fundal lens. Wisconsin
retinopathy grade [31] was recorded at each visit.
Surgical technique included full asepsis with povidone-
iodine washout of conjunctival sac pre-operatively and
subconjunctival cefuroxime at the completion of surgery.
All surgeries were completed under topical anaesthesia
with a self-sealing temporal corneal tunnel and a 6 mm
folding acrylic lens (SA60- Alcon).
At the completion of cataract surgery all patients had 4
mgs in 0.1 ml of triamcinolone acetate injected via the
inferotemporal pars plana, using a 27-gauge needle. The
injection was directed into the inferior vitreous cavity to
reduce the incidence of visually disturbing floaters post-
operatively and was given inferior to the temporal corneal
tunnel to avoid anterior chamber shallowing during scle-
ral perforation of the needle. Patients were seen on day
five, two weeks, two months and then three monthly
depending on clinical assessment. Best-corrected visual
acuities were obtained at two months post-operatively
with refraction.
Results
There were 12 patients with a total of 18 eyes. There were
10 patients (15 eyes) in group A and 3 patients (3 eyes) in
group B. There was one patient with one eye in group A
and one eye in group B. There were 8 females and 4 males
with a mean age of 69 years. Eleven of the twelve patients
were type two diabetics of which three were taking insu-
lin. Mean Haemoglobin A1C at the time of surgery was
8.7% (range 7.2–11.4%) and mean duration of diabetes
was 9 years (ranges 2–25 years). All of the 11 type two dia-
betic patients were being treated for hypertension.BMC Ophthalmology 2005, 5:15 http://www.biomedcentral.com/1471-2415/5/15
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Table 1: Pre-operative clinical characteristics of patients.
Group Patient number Age (years) DM type Pre-op PRP Pre-op Va Wisconsin 
Retinopathy 
Grade Pre-op
A 1 65 II No 6/60 Moderate
No CF Moderate
A 2 77 II No 6/60 Moderate
Yes CF LRPDR
A 3 73 II No 6/24 Mild
A 4 71 II No 6/60 Moderate
No CF Severe
A 5 67 II Yes HM HRPDR
A 6 72 II No 6/36 Moderate
No 6/24 Moderate
A 7 76 II No 6/24 Mild
A 8 68 II No 6/12 Mild
No 6/18 Moderate
A 9 71 II No 6/60 Severe
A 10 67 II No 6/36 Moderate
B 10 No (intra-op) HM Very Severe
B 11 69 II No (intra-op) HM Very Severe
B 12 49 I No 6/36 Mild
Mean age = 68.75
DM = Diabetes Mellitus; I = type one diabetes; II = type two diabetes; Pre-op = pre-operatively; PRP= pan retinal photocoagulation; Va = visual 
acuity; intra-op = intra-operatively; CF = counting fingers; HM = hand movements; LRPDR = low risk proliferative diabetic retinopathy; HRPDR= 
high risk proliferative diabetic retinopathy
Table 2: The post-operative clinical and visual outcomes of patients.
Group Patient Number Refracted Va two 
months post 
surgery
Last Va Macula clinically 
dry at two weeks
Macula clinically 
dry at last FU
A 1 6/9 6/18 Yes Yes
6/9 6/12 Yes Yes
A 2 6/12 6/12 Yes Yes
6/36 6/36 No No
A 3 6/18 6/18 Yes Yes
A 4 6/9 6/12 Yes No
CF CF No No
A 5 6/60 6/60 No No
A 6 6/36 6/36 Yes No
6/24 6/36 Yes No
A 7 6/6 6/6 Yes Yes
A 8 6/9 6/9 Yes Yes
6/9 6/12 Yes Yes
A 9 6/24 6/24 Yes No
A 10 6/18 6/18 Yes Yes
B 10 6/18 6/18 Yes No
B 11 6/12 6/12 Yes Yes
B 12 6/6 6/6 Yes Yes
Va = visual acuity; FU = follow up; CF = counting fingersBMC Ophthalmology 2005, 5:15 http://www.biomedcentral.com/1471-2415/5/15
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Pre-operative visual acuities ranged from 6/12 to hand
movements secondary to a combination of cataract and
maculopathy, with 16 of the 18 eyes having a visual acuity
of 6/24 or worse. Two patients in group B had intra-oper-
ative pan retinal photocoagulation (but not focal laser)
applied during phacoemulsification surgery. [Table 1]
Best-corrected visual acuities at two months post-opera-
tively ranged from 6/6 to CF with 9 eyes (50%) achieving
6/12 or better (7 eyes (47%) in group A and 2 eyes (67%)
in group B). No eyes had deterioration in visual acuity but
3 eyes (patients 4 and 6) had no recorded improvement in
acuity despite the fovea being clinically dry in two of these
cases (patient 6). [Table 2] The improvement in visual
acuity was significant at p = 0.001 using a Wilcoxon
matched-pairs test.
Fifteen eyes (83%) had clinically dry foveae at two weeks
post surgery – 12 (80%) in group A and all 3 (100%) in
group B. Last recorded visual acuities at a mean time of 8.5
months showed a deterioration from best-recorded visual
acuity in 5 (27%) patients because of recurrent macular
oedema – all in group A. [Table 2]
Six (33%) eyes; all in group A; showed a one-step or more
deterioration in retinopathy grade at last follow up (mean
follow up 8.5 months, range 4–15 months) compared
with pre-operative levels. All cases of progression occurred
five or more months post-operatively. [Table 3]
The triamcinolone was quick and easy to give and there
were no immediate operative complications from its
administration such as haemorrhage, capsule tears or pas-
sage of the triamcinolone into the anterior chamber. Post-
operatively 4 patients had transiently raised intraocular
pressure requiring treatment with ocular hypotensive
drops. None of these patients had pre -existing raised
intraocular pressure or were known steroid responders.
All 4 patients had normal pressures at the first visit but 2
developed raised pressure at two weeks(IOPs 34 and 29
mmHg) and the other 2 by 2 months (IOPs 31 and 24
mmHg). [Table 3] Three patients (patients 2, 4 and 8)
were treated successfully with topical beta blockers as a
monotherapy and 1 (patient 5) required combination
therapy with a topical beta blocker and a topical carbonic
anhydrase inhibitor. At 6 months post-operatively all
pressures were normal off treatment. Interestingly 2
patients (patients 2 and 4) who had both eyes operated
upon, developed high pressure in their second eyes after
having had no pressure rise in their first eye.
Three patients complained of visual floaters post-opera-
tively which settled within a few days. The retinal view was
unimpeded and accurate clinical examination was possi-
ble. There were no cases of endophthalmitis, uveitis, sig-
Table 3: Post-operative complications and deterioration in retinopathy grade on follow-up.
Group Patient Number Follow up (months) Raised IOP Stepwise deterioration 
in retinopathy grade at 
last FU (ETDRS)
A 11 5 3
14 1
A 26 0
8 Yes: 34 mmHg 0
A 39 0
A 41 0 0
12 Yes: 29 mm Hg 1
A 5 11 Yes: 31 mm Hg 0
A 61 0 1
70
A 71 2 0
A 85Y e s :  2 4  m m H g 1
50
A 97 1
A 10 6 0
B 10 4 0
B 11 8 0
B 12 4 0
Mean FU = 8.5
IOP = intraocular pressure; FU = follow-up; ETDRS = Early Treatment Diabetic Retinopathy StudyBMC Ophthalmology 2005, 5:15 http://www.biomedcentral.com/1471-2415/5/15
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nificant capsule phimosis or posterior capsule opacity in
the follow-up period. [Table 3]
Discussion
This pilot study suggests that intravitreal triamcinolone
can be given safely and easily at the time of phacoemulsi-
fication surgery.
We took care to inject the triamcinolone inferotemporally
away from the visual axis and anterior chamber to avoid
visually troublesome floaters and transit of triamcinolone
into the anterior chamber. The retinal view was unim-
paired post-operatively allowing accurate retinal assess-
ment and further laser treatment if needed. Similar to
other studies [32,33] we found only 22% of eyes devel-
oped increased intraocular pressure and all were treated
successfully with topical ocular hypotensive agents with
spontaneous improvement with time.
Intravitreal triamcinolone has been shown to lead to an
improvement in macular oedema and visual improve-
ment in diabetic patients not undergoing cataract surgery
[24-26] but has not; to our knowledge; been previously
studied in a series such as this.
Combining cataract surgery with triamcinolone rather
than giving triamcinolone before surgery as a separate
procedure avoided the potential for progression of lens
opacities associated with intraocular steroids [34,35]
which could have further interfered with retinopathy
assessment. We had no cases of endophthalmitis, which
can occur with triamcinolone injections [36,37]. Combin-
ing the two procedures reduces the patient's potential risk
of endophthalmitis from two separate intraocular epi-
sodes to one, whilst at the same time offering improved
patient convenience. The technique was simple adding
very little time to the procedure and in this series there was
no significant ocular morbidity associated with the triam-
cinolone. We choose to combine the procedure with our
standard clear corneal temporal incision phacoemulsifica-
tion technique. There is debate regarding the possibility of
an increased risk of endophthalmitis with temporal clear
corneal incisions [38]. However this has not been our
experience. We have had no increase in our rate of endo-
phthalmitis over the last five years during which a clear
corneal temporal approach has been adopted by all sur-
geons at our unit. Incidence of endophthalmitis in our
unit for 1999 was 0.11% and for 2004 was 0.09%, based
on approximately 6000 cases /year [39]. It is possible that
other factors such as wound construction and lid draping
and preparation are more important than incision posi-
tion itself [38]. All the cases in this series were done in the-
atre with full asepsis, topical povidone pre-operatively,
careful lid draping and carefully constructed wounds,
which were watertight at the close of surgery. These are
important factors in avoiding infective complications.
We had no cases of posterior capsule rupture in this series.
Triamcinolone has been used to help visualise vitreous
during posterior capsule rupture and anterior vitrectomy
[40] and anecdotally in cases of phacoemulsification sur-
gery with posterior capsule rupture to reduce the inci-
dence of post operative cystoid macular oedema and
postoperative inflammation [41]. Potentially therefore
intravitreal triamcinolone administration could be con-
sidered even if posterior capsule rupture was to occur
although we have no experience of this.
The natural history of patients with foveal oedema at the
time of cataract surgery is recognised as being poor and
the patients in the study had a number of other features
associated with a particularly poor prognosis after cataract
surgery- increasing age, female sex, poor glycaemic control
with high Haemoglobin A 1C (%) at the time of surgery
and moderate to severe background retinopathy changes,
have all been associated with a poor prognosis in other
studies [12,13,16,18]. All the patients in group A had
chronic macular oedema prior to cataract surgery, which
had been unresponsive to treatment. Indeed patients such
as these with chronic unresponsive macular oedema, par-
ticularly if there is only a moderate degree of cataract, are
often declined surgery on the basis that the maculopathy
would limit the underlying visual acuity, which can also
deteriorate with surgery. Despite this approximately 50%
of these patients achieved 6/12 vision.
Patients who present with dense cataracts and significant
retinopathy, especially maculopathy, which is untreatable
pre-operatively because of the lens opacities, pose a diffi-
cult clinical scenario. Laser can be performed post-opera-
tively but this can be difficult, for reasons previously
stated and surgically induced inflammation. There were
three patients in the study in this group – group B. Two of
these patients had very severe non proliferative retinopa-
thy, in addition to maculopathy, and were treated with
intra-operative PRP which can also exacerbate macular
oedema. Despite these difficulties and risk factors for mac-
ulopathy exacerbation all three patients had complete
macular oedema resolution at the two week examination
without any macular laser having been applied at that
stage.
Overall fifteen (83%) of the patients had complete resolu-
tion of their macular oedema at two weeks follow up.
Recurrence of macular oedema occurred in some patients
in this study as would be expected from the known short
term effect of intravitreal triamcinolone and other studies
with intravitreal triamcinolone and diabetic macular
oedema. However the triamcinolone clearly prevented theBMC Ophthalmology 2005, 5:15 http://www.biomedcentral.com/1471-2415/5/15
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short term exacerbation of macular oedema that can be
associated with blood ocular breakdown due to intraocu-
lar surgery and PRP [23,29,42]. It seems logical to use a
drug, albeit with a known short-lived effect, in this way to
potentially improve visual outcome until longer lasting
alternatives are produced.
Retinopathy progression occurred during follow up in
only six patients (none within 5 months of surgery and 4
out of 6 at more than 10 months following surgery) and
it may be that triamcinolone has a role in reducing the
deterioration of retinopathy that has been reported fol-
lowing cataract surgery especially in patients with more
advanced retinopathy. It may also have a role in the inhi-
bition of retinal neovascularisation [43,44]. Numbers in
this uncontrolled pilot study are too limited to draw any
definitive conclusions.
Triamcinolone was only injected in those eyes with pre-
existing macular oedema at the time of cataract surgery. It
was not used in eyes thought to be at risk of developing
macular oedema after surgery in those with clinically dry
foveae at the time of surgery. The natural history of
patients with dry maculae at the time of surgery who
develop macular oedema following surgery is relatively
good [22] and it was felt that the risks associated with tri-
amcinolone in that group would outweigh the benefits. At
present we are not recommending triamcinolone in that
group of patients, although this may merit further
investigation.
Conclusion
This pilot study suggests that intravitreal triamcinolone
can be given safely and easily at the time of phacoemulsi-
fication surgery in patients with visually significant cata-
ract and diabetic foveal macular oedema. Eighty-three
percent of the eyes in this study had complete resolution
of macular oedema at two weeks post-operatively and
none experienced any exacerbation of their maculopathy.
Further controlled studies are needed to demonstrate the
potential visual advantages and long-term benefit of this
treatment approach.
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